Ten years lat­er, Lil­ly's long-term Alzheimer's tri­al of solanezum­ab has de­fin­i­tive­ly failed

A tri­al of Eli Lil­ly’s Alzheimer’s drug solanezum­ab that be­gan in 2013 didn’t show any ben­e­fit in pa­tients, who were fol­lowed for a decade to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.